oxidopamine has been researched along with Liver Steatosis in 1 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oben, JA | 1 |
| Roskams, T | 1 |
| Yang, S | 1 |
| Lin, H | 1 |
| Sinelli, N | 1 |
| Li, Z | 1 |
| Torbenson, M | 1 |
| Huang, J | 1 |
| Guarino, P | 1 |
| Kafrouni, M | 1 |
| Diehl, AM | 1 |
1 other study available for oxidopamine and Liver Steatosis
| Article | Year |
|---|---|
Sympathetic nervous system inhibition increases hepatic progenitors and reduces liver injury.
Topics: Adrenergic alpha-Antagonists; Animals; Antioxidants; Body Weight; Diet; Fatty Liver; Hepatocytes; Li | 2003 |